SAFETY DATA SHEET

GlaxoSmithKline

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material **ANECTINE INJECTION**

Synonyms ANECTINE INJECTION 20MG/ML * ANECTINE INJECTION 50MG/ML * ANECTINE INJECTABLE * NDC NO 0173-0071-95 * SUXAMETHONIUM CHLORIDE, FORMULATED PRODUCT

Company Name

GlaxoSmithKline, Corporate Environment, Health & Safety
980 Great West Road
Brentford, Middlesex TW8 9GS UK

UK General Information:	+44-20-8047-5000
Transport Emergency (EU)	+44-1865-407333
Medical Emergency	+1-612-221-3999, Ext 221
Information and Advice:	US number, available 24 hours
	Multi-language response

GlaxoSmithKline, Corporate Environment, Health & Safety
2200 Renaissance Blvd, Suite 105
King of Prussia, PA 19406 US

US General Information:	+1-888-825-5249
Transport Emergency (non EU)	+1-703-527-3887
	US number, available 24 hours
	Multi-language response

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS RN	Percentage
SUXAMETHONIUM CHLORIDE	71-27-2	2.3 to 5.25
NON-HAZARDOUS INGREDIENTS	Unassigned	94.75 to 97.70

3. HAZARDS IDENTIFICATION

Fire and Explosion Expected to be non-combustible.

*** Health** Caution - Pharmaceutical agent. Handling this product in its final form presents minimal risk from occupational exposure.
Health effects information is based on hazards of components. Respiratory allergen.
Possible effects of overexposure in the workplace include: paralysis; respiratory failure; irregular heartbeat; muscle cramps.

Environment No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.
Health Surveillance Procedures	Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	This product is non-combustible, although the packaging is combustible.
Extinguishing Media	Water is recommended for fires involving packaging.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	Prevent entry into waterways, sewers, surface drainage systems and poorly ventilated areas.
Clean-up Methods	Spread an inert absorbent on the spill and place in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	Water can be used for clean-up and decontamination operations.

7. HANDLING AND STORAGE

HANDLING

General Requirements	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
STORAGE	No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

INGREDIENT	SUXAMETHONIUM CHLORIDE	
GSK Occupational Hazard Category	2	
GSK Occupational Exposure Limit	100 mcg/m3 (15 MIN STEL)	RESPIRATORY SENSITISER

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection	Wear approved safety glasses with side shields if eye contact is possible.
Respirators	If respiratory protective equipment (RPE) is used, the type of RPE will depend upon air concentrations present, required protection factor as well as hazards, physical properties and warning properties of substances present.
Other Equipment or Procedures	None required for normal handling. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Clarity	Clear.
Colour	Colourless.
Physical Form	Aqueous solution.

10. STABILITY AND REACTIVITY

Stability	DO NOT FREEZE - dispose of properly if frozen.
Conditions to Avoid	None for normal handling of this product.

11. TOXICOLOGICAL INFORMATION

Oral Toxicity	No studies have been conducted.
Skin Effects	Irritation might occur following direct contact.
Eye Effects	Irritation might occur following direct contact with eyes.
Target Organ Effects	Adverse effects might occur in the following organ(s) following overexposure: peripheral nervous system; respiratory system.
Sensitisation	Allergic skin reactions might occur following dermal exposure.
Genetic Toxicity	This product contains suxamethonium chloride which produced evidence of DNA damage in the following assay(s): in vitro cytogenetics assay; mouse micronucleus test. Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity	No studies have been conducted and this material is not listed as a carcinogen by GSK, IARC, NTP or US OSHA.
Reproductive Effects	Insufficient information available to classify for reproductive toxicity.
Pharmacological Effects	This material is a muscle relaxant for use during anaesthesia. Adverse effects of overexposure might include: paralysis; respiratory failure; irregular heartbeat; muscle cramps.
*** Other Adverse Effects**	None known for occupational exposure.

12. ECOLOGICAL INFORMATION

Summary	No information is available about the potential of this product to produce adverse environmental effects. Local regulations and procedures should be consulted prior to environmental release.

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations	Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
Regulatory Requirements	Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information	Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

*** EU Classification and Labelling**

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification	This product is classified as hazardous according to the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status	Exempt

16. OTHER INFORMATION

References	GSK Hazard Determination

Date Approved/Revised 20-Jul-2005 **SDS Version Number** 7

SDS Sections Updated

Sections	Subsections
COMPOSITION / INFORMATION ON INGREDIENTS	
FIRST-AID MEASURES	Medical Conditions Caused or Aggravated by Exposure
REGULATORY INFORMATION	European Union Classification and Labelling Requirements
	US Environmental (EPA) Requirements
TOXICOLOGY INFORMATION	Other Adverse Effects

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.